Literature DB >> 28944778

Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy.

Antoine Barbari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28944778     DOI： 10.1038/nrneph.2017.134

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  14 in total

Review 1.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

2.  A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.

Authors:  Henrik E Mei; Ina Wirries; Daniela Frölich; Mikael Brisslert; Claudia Giesecke; Joachim R Grün; Tobias Alexander; Stefanie Schmidt; Katarzyna Luda; Anja A Kühl; Robby Engelmann; Michael Dürr; Tobias Scheel; Maria Bokarewa; Carsten Perka; Andreas Radbruch; Thomas Dörner
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

Review 3.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 4.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

Review 5.  Targeting B cells and antibody in transplantation.

Authors:  M R Clatworthy
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

Review 6.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

Review 7.  Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Lancet       Date:  2015-05-16       Impact factor: 79.321

8.  Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

Authors:  Gustaaf W van Imhoff; Andrew McMillan; Matthew J Matasar; John Radford; Kirit M Ardeshna; Kazimierz Kuliczkowski; WonSeog Kim; Xiaonan Hong; Jette Soenderskov Goerloev; Andrew Davies; María Dolores Caballero Barrigón; Michinori Ogura; Sirpa Leppä; Michael Fennessy; Qiming Liao; Bronno van der Holt; Steen Lisby; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

9.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Authors:  Piero Ruggenenti; Hanna Debiec; Barbara Ruggiero; Antonietta Chianca; Timothee Pellé; Flavio Gaspari; Flavio Suardi; Elena Gagliardini; Silvia Orisio; Ariela Benigni; Pierre Ronco; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

10.  Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.

Authors:  Karine Dahan; Hanna Debiec; Emmanuelle Plaisier; Marine Cachanado; Alexandra Rousseau; Laura Wakselman; Pierre-Antoine Michel; Fabrice Mihout; Bertrand Dussol; Marie Matignon; Christiane Mousson; Tabassome Simon; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2016-06-27       Impact factor: 10.121
View more
  1 in total

1.  Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.

Authors:  Vincenzo L'Imperio; Federico Pieruzzi; Renato Alberto Sinico; Manuela Nebuloni; Antonio Granata; Andrew Smith; Antonella Radice; Fabio Pagni
Journal:  J Nephrol       Date:  2018-04-06       Impact factor: 3.902
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.